Low Testosterone in Men with Cardiovascular Disease or Risk Factors: To Treat or Not To Treat?

Area of Science:

• Endocrinology
• Cardiology
• Men's Health

Background:

• Hypogonadism, characterized by low testosterone and symptoms like fatigue and erectile dysfunction, is linked to increased cardiovascular risk.
• The cardiovascular safety and efficacy of testosterone replacement therapy (TRT) in men with hypogonadism remain debated, with mixed evidence.
• Men with symptomatic hypogonadism and existing cardiovascular disease (CVD) or risk factors require a balanced approach to TRT.

Approach:

• Review of current evidence on testosterone replacement therapy (TRT) in men with hypogonadism and cardiovascular disease (CVD) or risk factors.
• Analysis of existing data regarding the cardiovascular benefits and harms of TRT.
• Consideration of clinical guidelines and the need for further prospective research.

Key Points:

• TRT for symptomatic hypogonadism is generally supported for non-cardiac symptom relief, even in men with CVD or risk factors.
• Current evidence suggests TRT is likely safe for men with CVD or risk factors and may reduce major adverse cardiovascular events (MACE).
• Improved prospective data and large randomized trials are necessary to definitively assess TRT's impact on MACE.

Conclusions:

• TRT can be considered for symptomatic hypogonadism in men with CVD or risk factors, balancing symptom relief with ongoing research needs.
• While likely safe and potentially beneficial for cardiovascular health, TRT requires careful patient selection, appropriate dosing, and regular monitoring.
• Further large-scale, prospective randomized trials are crucial to establish definitive cardiovascular outcomes and inform clinical recommendations for TRT.